Topics

Paion (PA8) - Acacia to sell ByFavo in US

13:08 EST 14 Jan 2020 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - Paion: Acacia Pharma will sell ByFavo (remimazolam) in the US after a deal with Cosmo (Paion’s Switzerland-based US partner). Cosmo estimates 24.5m endoscopy procedures per year. Acacia may launch its first US product, BARHEMSYS, from mid-2020 but has limited US infrastructure and, as yet, no salesforce. We are updating our Paion valuation (formerly €317m).
ISIN: DE000A0B65S3

Original Article: Paion (PA8) - Acacia to sell ByFavo in US

NEXT ARTICLE

More From BioPortfolio on "Paion (PA8) - Acacia to sell ByFavo in US"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...